Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

ALSUntangled #79: alpha-lipoic acid

  • Alaina Giacobbe
  • , James Hiana
  • , Olivia Wang
  • , Michael Benatar
  • , Paul Wicks
  • , Javier Mascias Cadavid
  • , Sartaj Jhooty
  • , Christopher McDermott
  • , Gary Pattee
  • , Tulio Bertorini
  • , Terry Heiman-Patterson
  • , Dylan Ratner
  • , Paul Barkhaus
  • , Gregory Carter
  • , Carlayne Jackson
  • , Keelie Denson
  • , Andrew Brown
  • , Carmel Armon
  • , Yuyao Sun
  • , Andre Nguyen
  • Richard Bedlack, Xiaoyan Li

Producción científica: Review articlerevisión exhaustiva

Resumen

Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It serves as an essential cofactor for enzymatic reactions in mitochondrial energy production, is a potent antioxidant and has anti-inflammatory effects, which are plausible mechanisms in slowing ALS progression. In ALS preclinical studies, ALA slowed motor function decline and improved survival. There were self-reported cases of improved muscle strength in ALS patients when ALA was taken with numerous additional supplements, making it difficult to discern its efficacy. One small, 6-month open-label study showed improved quality of life, fatigue, and mood after participants took it with B vitamins and amino acids for the first 3 months. So far, no clinical trials have been published in people living with amyotrophic lateral sclerosis (PALS). Given the insufficient clinical data, we cannot endorse ALA and will support more research on its efficacy in slowing ALS progression.

Idioma originalEnglish (US)
Páginas (desde-hasta)233-237
Número de páginas5
PublicaciónAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volumen27
N.º1-2
DOI
EstadoPublished - 2026

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Huella

Profundice en los temas de investigación de 'ALSUntangled #79: alpha-lipoic acid'. En conjunto forman una huella única.

Citar esto